The Yale Secret Shopper Study: The 4 Providers That Passed vs. the 45 That Didn't
A JAMA-published secret shopper study from early July 2026 sent researchers posing as patients to 49 GLP-1 telehealth platforms. Forty-five prescribed with minimal oversight. Four didn't. Here's the actual breakdown — not the sanitized version.
What the researchers actually did
Trained researchers submitted standardized patient profiles to 49 telehealth platforms offering GLP-1 prescriptions, then evaluated the quality and rigor of the clinical review each platform provided before issuing a prescription.
The uncomfortable finding
45 of 49 platforms prescribed with what researchers characterized as minimal clinical oversight. Roughly two-thirds involved zero direct interaction with a prescribing clinician before medication was approved — approval happened largely off the intake questionnaire alone.
What separated the 4 that passed
The platforms that demonstrated genuine clinical rigor shared common traits: actual clinician review with follow-up questions when something in the intake warranted it, documented monitoring plans beyond the initial prescription, and evaluation processes that could reasonably catch a contraindication rather than rubber-stamping standardized answers.
Embody From consult
Injectable semaglutide with documented clinical review as part of standard process.
Visit Embody →Paid linkSesame Care $175
Prescribes FDA-approved brand-name medications through a licensed provider network.
What to actually do with this
Before your next evaluation, ask directly: will a clinician review my specific answers, or does approval happen automatically? A provider that answers plainly is behaving differently than the 45 this study flagged.